LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, ...

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

TORONTO--(BUSINESS WIRE)--Security Compass, a leading cybersecurity solution provider, has published the results of a new research report, “2022 DevSecOps Perspectives on AppSec Training”. This study ...

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

This open-label study included 19 patients from clinical sites in Ireland and the United States. The majority of patients were female (68.4%) and the average age was 42 years. The primary endpoint was ...

TORONTO--(BUSINESS WIRE)--Security Compass, a leading cybersecurity solutions provider, today released the results of a commissioned Total Economic Impact™ (TEI) study conducted by Forrester ...

The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a ...

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.

Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy endpoint for COMPANION-002, the company’s ongoing Phase 2/3 trial of ...

Open-label Phase 2 study shows a single 25 mg COMP360 psilocybin dose was well tolerated, with no serious adverse events observed, and indicated both rapid and durable improvement in symptoms from ...